FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacynews2024-11-07T17:02:53+00:00November 7th, 2024|Endpoints News|
California voters say yes to restrictions around 340B spendingnews2024-11-06T19:58:47+00:00November 6th, 2024|Endpoints News|
Biotech industry worries over potential for RFK Jr. ally as FDA picknews2024-11-06T15:00:20+00:00November 6th, 2024|Endpoints News|
New Trump era could be a boon for biopharma M&A, dealmakingnews2024-11-06T12:22:52+00:00November 6th, 2024|Endpoints News|
Acadia lands $150M sale of rare pediatric PRVnews2024-11-06T12:04:59+00:00November 6th, 2024|Endpoints News|
FDA cites Mark Cuban’s drug compounding center in Dallas with sterility, quality concernsnews2024-11-04T21:14:27+00:00November 4th, 2024|Endpoints News|
The election is Tuesday. What’s at stake for the pharma industry?news2024-11-04T21:07:35+00:00November 4th, 2024|Endpoints News|
Rare disease biopharma companies weigh in on FDA’s new innovation hubnews2024-11-04T20:14:53+00:00November 4th, 2024|Endpoints News|
FDA expands faster drug review pilot from supplemental to full applicationsnews2024-11-04T18:07:00+00:00November 4th, 2024|Endpoints News|
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDEÒ Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Diseasenews2024-11-04T14:33:59+00:00November 4th, 2024|Medical Device News Magazine|
